Ipamorelin vs Somatropin
Overview
Ipamorelin is primarily a performance & growth peptide, while Somatropin is used for hormonal.
This page compares Ipamorelin and Somatropin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Ipamorelin | Somatropin | |
|---|---|---|
| Category | Performance & Growth | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 200-300 mcg | 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) |
| Frequency | twice-daily | daily subcutaneous injection |
| Reported benefits | Natural GH release, improved body composition, better sleep, anti-aging effects, no appetite increase | In labeled use, somatropin increases linear growth in children with growth failure from growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small size for gestational age and idiopathic short stature. In adults with diagnosed growth hormone deficiency, professional guidelines describe benefits in body composition, exercise capacity, skeletal integrity and quality-of-life measures, with the largest benefit in the most severely deficient patients. |
| Reported side effects | Very well-tolerated. Rare: headache, injection site reactions | Fluid retention, edema, arthralgia and carpal tunnel syndrome are common in adults. Labeled warnings include glucose intolerance and new-onset diabetes, intracranial hypertension, slipped capital femoral epiphysis and scoliosis progression in children, hypothyroidism, hypoadrenalism, pancreatitis and hypersensitivity reactions. |
Key differences
Primary use. Ipamorelin is categorised under Performance & Growth, while Somatropin falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Ipamorelin: not FDA-approved; treated as a research compound. Somatropin: FDA-approved.
Dosing. Ipamorelin is typically dosed at 200-300 mcg (twice-daily). Somatropin is typically dosed at 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) (daily subcutaneous injection).
Can you stack them?
Some protocols combine peptides, but stacking Ipamorelin and Somatropin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Ipamorelin and Somatropin?
- Ipamorelin is primarily a performance & growth peptide, while Somatropin is used for hormonal. Ipamorelin is not FDA-approved; generally classified as a research compound, whereas Somatropin is FDA-approved for one or more indications.
- What is Ipamorelin used for?
- GH secretagogue, anti-aging.
- What is Somatropin used for?
- Recombinant human growth hormone, FDA-approved for growth failure in children and growth hormone deficiency in adults.
- Can you take Ipamorelin and Somatropin together?
- Some users combine peptides within a single protocol, but stacking Ipamorelin and Somatropin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Ipamorelin or Somatropin FDA-approved?
- Ipamorelin is not FDA-approved; generally classified as a research compound. Somatropin is FDA-approved for one or more indications.
Read the full articles
- Ipamorelin — full monograph: mechanism, research, dosing & references
- Somatropin — full monograph: mechanism, research, dosing & references